Recommended Topic Related To:

Xtandi

"The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.

The FDA initially appr"...

Xtandi

SIDE EFFECTS

The following is discussed in more detail in other sections of the labeling:

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In the randomized clinical trial in patients with metastatic castration-resistant prostate cancer who had previously received docetaxel, patients received XTANDI 160 mg orally once daily (N = 800) or placebo (N = 399). The median duration of treatment was 8.3 months with XTANDI and 3.0 months with placebo. All patients continued androgen deprivation therapy. Patients were allowed, but not required, to take glucocorticoids. During the trial, 48% of patients on the XTANDI arm and 46% of patients on the placebo arm received glucocorticoids. All adverse events and laboratory abnormalities were graded using NCI CTCAE version 4.

The most common adverse drug reactions ( ≥ 5%) reported in patients receiving XTANDI in the randomized clinical trial were asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension. Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients and 53% of placebo-treated patients. Discontinuations due to adverse events were reported for 16% of XTANDI-treated patients and 18% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0.9% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients. Table 1 shows adverse reactions reported in the randomized clinical trial that occurred at a ≥ 2% absolute increase in frequency in the XTANDI arm compared to the placebo arm.

Table 1: Adverse Reactions in the Randomized Trial

  XTANDI
N = 800
Placebo
N = 399
Grade 1-4
(%)
Grade 3-4
(%)
Grade 1-4
(%)
Grade 3-4
(%)
General Disorders
  Asthenic Conditionsa 50.6 9 44.4 9.3
  Peripheral Edema 15.4 1 13.3 0.8
Musculoskeletal And Connective Tissue Disorders
  Back Pain 26.4 5.3 24.3 4
  Arthralgia 20.5 2.5 17.3 1.8
  Musculoskeletal Pain 15 1.3 11.5 0.3
  Muscular Weakness 9.8 1.5 6.8 1.8
  Musculoskeletal Stiffness 2.6 0.3 0.3 0
Gastrointestinal Disorders
  Diarrhea 21.8 1.1 17.5 0.3
Vascular Disorders
  Hot Flush 20.3 0 10.3 0
  Hypertension 6.4 2.1 2.8 1.3
Nervous System Disorders
  Headache 12.1 0.9 5.5 0
  Dizzinessb 9.5 0.5 7.5 0.5
  Spinal Cord Compression and Cauda Equina Syndrome 7.4 6.6 4.5 3.8
  Paresthesia 6.6 0 4.5 0
  Mental Impairment Disordersc 4.3 0.3 1.8 0
  Hypoesthesia 4 0.3 1.8 0
Infections And Infestations
  Upper Respiratory Tract Infectiond 10.9 0 6.5 0.3
  Lower Respiratory Tract And Lung Infectione 8.5 2.4 4.8 1.3
Psychiatric Disorders
  Insomnia 8.8 0 6 0.5
  Anxiety 6.5 0.3 4 0
Renal And Urinary Disorders
  Hematuria 6.9 1.8 4.5 1
  Pollakiuria 4.8 0 2.5 0
Injury, Poisoning And Procedural Complications
  Fall 4.6 0.3 1.3 0
  Non-pathologic Fractures 4 1.4 0.8 0.3
Skin And Subcutaneous Tissue Disorders
  Pruritus 3.8 0 1.3 0
  Dry Skin 3.5 0 1.3 0
Respiratory Disorders
  Epistaxis 3.3 0.1 1.3 0.3
a Includes asthenia and fatigue.
b Includes dizziness and vertigo.
c Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.
d Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.
e Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.

Laboratory Abnormalities

In the randomized clinical trial, Grade 1-4 neutropenia occurred in 15% of patients on XTANDI (1% Grade 3-4) and in 6% of patients on placebo (no Grade 3-4). The incidence of Grade 1-4 thrombocytopenia was similar in both arms; 0.5% of patients on XTANDI and 1% on placebo experienced Grade 3-4 thrombocytopenia. Grade 1-4 elevations in ALT occurred in 10% of patients on XTANDI (0.3% Grade 3-4) and 18% of patients on placebo (0.5% Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3% of patients on XTANDI and 2% of patients on placebo.

Infections

In the randomized clinical trial, 1.0% of patients treated with XTANDI compared to 0.3% of patients on placebo died from infections or sepsis. Infection-related serious adverse events were reported in approximately 6% of the patients on both treatment arms.

Falls and Fall-related Injuries

In the randomized clinical trial, falls or injuries related to falls occurred in 4.6% of patients treated with XTANDI compared to 1.3% of patients on placebo. Falls were not associated with loss of consciousness or seizure. Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas.

Hallucinations

In the randomized clinical trial, 1.6% of patients treated with XTANDI were reported to have Grade 1 or 2 hallucinations compared to 0.3% of patients on placebo. Of the patients with hallucinations, the majority were on opioid-containing medications at the time of the event. Hallucinations were visual, tactile, or undefined.

Read the Xtandi (enzalutamide capsules) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Drugs that Inhibit or Induce CYP2C8

Co-administration of a strong CYP2C8 inhibitor (gemfibrozil) increased the composite area under the plasma concentration-time curve (AUC) of enzalutamide plus N-desmethyl enzalutamide in healthy volunteers. Co-administration of XTANDI with strong CYP2C8 inhibitors should be avoided if possible. If co-administration of XTANDI with a strong CYP2C8 inhibitor cannot be avoided, reduce the dose of XTANDI [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY].

The effects of CYP2C8 inducers on the pharmacokinetics of enzalutamide have not been evaluated in vivo. Co-administration of XTANDI with strong or moderate CYP2C8 inducers (e.g., rifampin) may alter the plasma exposure of XTANDI and should be avoided if possible. Selection of a concomitant medication with no or minimal CYP2C8 induction potential is recommended [see CLINICAL PHARMACOLOGY].

Drugs that Inhibit or Induce CYP3A4

Co-administration of a strong CYP3A4 inhibitor (itraconazole) increased the composite AUC of enzalutamide plus Ndesmethyl enzalutamide by 1.3 fold in healthy volunteers [see CLINICAL PHARMACOLOGY].

The effects of CYP3A4 inducers on the pharmacokinetics of enzalutamide have not been evaluated in vivo. Co-administration of XTANDI with strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine) may decrease the plasma exposure of XTANDI and should be avoided if possible. Selection of a concomitant medication with no or minimal CYP3A4 induction potential is recommended. Moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, nafcillin) and St. John's Wort may also reduce the plasma exposure of XTANDI and should be avoided if possible [see CLINICAL PHARMACOLOGY].

Effect of XTANDI on Drug Metabolizing Enzymes

Enzalutamide is a strong CYP3A4 inducer and a moderate CYP2C9 and CYP2C19 inducer in humans. At steady state, XTANDI reduced the plasma exposure to midazolam (CYP3A4 substrate), warfarin (CYP2C9 substrate), and omeprazole (CYP2C19 substrate). Concomitant use of XTANDI with narrow therapeutic index drugs that are metabolized by CYP3A4 (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus and tacrolimus), CYP2C9 (e.g., phenytoin, warfarin) and CYP2C19 (e.g., S-mephenytoin) should be avoided, as enzalutamide may decrease their exposure. If co-administration with warfarin cannot be avoided, conduct additional INR monitoring [see CLINICAL PHARMACOLOGY].

Read the Xtandi Drug Interactions Center for a complete guide to possible interactions

Last reviewed on RxList: 9/18/2012
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.